Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Background: Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil. Objectives: The objective of this review was to assess the effects of Nicobrevin on long-term smoking cessation Search methods: We searched the Cochrane Tobacco Addiction Group trials register. Most recent search was January 2009. Selection criteria: Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up. Data collection and analysis: Data were sought on the outcome, method of randomisation, and completeness of follow up. Main results: We identified no trials meeting the full inclusion criteria including long-term follow-up. Authors' conclusions: There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.

Original publication




Journal article


Cochrane Database of Systematic Reviews

Publication Date